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Abstract.
Background: Studies on the systemic availability of nutrients and nutritional status in Alzheimer’s disease (AD) are widely
available, but the majority included patients in a moderate stage of AD.
Objective: This study compares the nutritional status between mild AD outpatients and healthy controls.
Methods: A subgroup of Dutch drug-naı¨ve patients with mild AD (Mini-Mental State Examination (MMSE) ≥20) from the
Souvenir II randomized controlled study (NTR1975) and a group of Dutch healthy controls were included. Nutritional status
was assessed by measuring levels of several nutrients, conducting the Mini Nutritional Assessment (MNA®) questionnaire and
through anthropometric measures.
Results: In total, data of 93 healthy cognitively intact controls (MMSE 29.0 [23.0–30.0]) and 79 very mild AD patients
(MMSE = 25.0 [20.0–30.0]) were included. Plasma selenium (p < 0.001) and uridine (p = 0.046) levels were significantly lower
in AD patients, with a similar trend for plasma vitamin D (p = 0.094) levels. In addition, the fatty acid profile in erythrocyte
membranes was different between groups for several fatty acids. Mean MNA screening score was significantly lower in AD
patients (p = 0.008), but not indicative of malnutrition risk. No significant differences were observed for other micronutrient or
anthropometric parameters.
Conclusion: In non-malnourished patients with very mild AD, lower levels of some micronutrients, a different fatty acid profile
in erythrocyte membranes and a slightly but significantly lower MNA screening score were observed. This suggests that subtle
differences in nutrient status are present already in a very early stage of AD and in the absence of protein/energy malnutrition.
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INTRODUCTION
Alzheimer’s disease (AD) is a progressive, neu-
rodegenerative disorder with unknown etiology. There
are multiple risk factors for AD including age, cer-
tain genetic alleles (e.g., apolipoprotein E4), and
specific nutritional characteristics [1–3]. Epidemio-
logical studies suggest that a low intake of n-3 fatty
acids, B-vitamins, and antioxidants increases the risk
of AD [4, 5]. Several nutrients are hypothesized to
play a role in the pathological processes of AD. For
instance, the n-3 long-chain polyunsaturated fatty acid
(n-3 LC-PUFA) docosahexaenoic acid (DHA) reduces
abnormal amyloid- (A) and tau processing [6]. In
addition, antioxidants like vitamin E have been shown
to protect against A-induced oxidative stress and to
stabilize neuronal membranes [7]. These observations
suggest that systemic availability of several nutrients
is of importance in AD.
AD patients are frequently reported to have lower
plasma levels of certain nutrients compared with cog-
nitively intact controls. These lower plasma nutrient
levels may be due to reduced daily consumption,
increased nutrient use and/or a different metabolism
in AD [8]. Recently, a systematic review and meta-
analysis compared plasma levels of vitamins, minerals,
trace elements, and fatty acids in AD patients with
those in cognitive intact controls [9]. Significantly
lower plasma levels of vitamin A, C, E, folate, and
vitamin B12 were found in AD patients, while there
was a trend for lower levels of vitamin D and zinc
[9]. About half of the studies included in this review
mentioned the stage of the disease of the included
AD patients [9], reporting average Mini-Mental State
Examination (MMSE) scores ranging from 8 to 21.5.
This suggests that limited data are available on nutri-
ent levels in very mild AD patients. Besides lower
micronutrient levels, (risk on) protein/energy malnutri-
tion frequently occurs in cognitively impaired elderly
subjects [10], and data suggest a positive association
between the presence of (risk of) protein/energy mal-
nutrition and the stage of AD [11–14]. Protein/energy
malnutrition can potentially be associated with differ-
ential blood nutrient levels [15]. Furthermore, (risk of)
protein/energy malnutrition as assessed by the Mini
Nutritional Assessment (MNA®) questionnaire has
been shown to be associated with disease progression
in very mild AD patients [16], indicating the impor-
tance of studying nutritional status in the early stage
of AD.
The aim of the current study was to compare
the nutritional status between mild AD patients and
healthy controls. We assessed nutritional status by
measuring levels of several micronutrients and fatty
acids. We used the MNA questionnaire and anthropo-
metric measures to determine (risk of) protein/energy
malnutrition. The current study is a substudy of the
24-week, double-blind, randomized, controlled, multi-
center Souvenir II study in which the effect of a medical
food on memory performance of mild AD patients was
investigated [17].
MATERIALS AND METHODS
Study population
The study population of this exploratory Souvenir II
substudy consisted of a subgroup of patients with mild
AD from the double-blind, randomized, controlled,
multi-center, multi-country Souvenir II study and a
group of healthy controls, all recruited in the Nether-
lands. The Dutch Trial Registration Number for the
Souvenir II study is NTR1975.
Patients
A total of 84 AD patients across nine study centers
agreed to participate. The methodology of the Souvenir
II study has been described in detail previously [17].
Briefly, major eligibility criteria included 1) diagno-
sis of probable AD according to the National Institute
of Neurological and Communicative Disorders and
Stroke and the Alzheimer’s Disease and Related Disor-
ders Association criteria [18], 2) mild AD as defined by
a MMSE score ≥20, 3) age ≥50 years, 4) being drug-
naı¨ve for AD medication (cholinesterase inhibitor or
N-methyl-D-aspartate receptor antagonist, 5) the pres-
ence of a responsible caregiver, and 6) the provision
of written informed consent from both the patient and
caregiver.
Healthy controls
A total of 98 healthy controls were included across
seven (out of nine) Dutch study centers. Healthy con-
trols could be either caregivers, other contacts of the
patients or other volunteers and met the following
eligibility criteria: 1) age ≥50 years, 2) no current diag-
nosis of AD, 3) no other condition that might interfere
with the definition ‘healthy person’ according to the
investigator’s judgment, 4) no participation in another
interventional clinical study, and 5) the provision of
written informed consent.
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Nutritional supplement use
In addition to the eligibility criteria described above,
the following exclusion criteria regarding the use of
nutritional supplements or dietary habits were applied
to both the inclusion of AD patients and healthy
controls: 1) use within two months prior to study par-
ticipation of a) n-3 fatty acid containing supplements or
b) oily fish (when consumed more than twice a week)
and 2) use within one month prior to study participation
of a) vitamins B, C and/or E > 200% of recommended
daily intake or b) high energy and/or high protein nutri-
tional supplements and/or medical foods.
Study procedures
For the current analysis, the authors used data on
nutritional status collected at the baseline visit of the
Souvenir II study for the AD patients and data col-
lected at a single time-point for the healthy controls. In
addition, information on demographic data and the use
of nutritional supplements was collected from all sub-
jects. At all centers, trained research nurses performed
all assessments.
Outcome measures
Plasma micronutrients and fatty acids in plasma phos-
pholipids and erythrocyte membrane: Non-fasting
blood samples were taken to determine plasma folate,
vitamins B6 and B12, choline, homocysteine (Hcy),
uridine, vitamins A, D, and E, selenium, albumin, and
plasma phospholipid fatty acids levels. In addition,
erythrocytes were collected from the same blood sam-
ple to determine fatty acid levels in the erythrocyte
membrane.
Anthropometry: Measures of anthropometry included
calf circumference and body weight and height to
calculate body mass index (BMI) (=body weight
[kg]/body height [m]2). Calf circumference was
assessed to the nearest 0.1 cm of the largest part of the
left lower leg using calibrated equipment, with the sub-
ject in a sitting position, knee and ankle at a 90◦ angle
and with the muscles relaxed. Body height was mea-
sured, without shoes, to the nearest cm. Body weight
was measured, without shoes and heavy clothing, to
the nearest 0.1 kg.
Mini Nutritional Assessment: The MNA® question-
naire was used as a measure of nutritional status
[19–21]. The questionnaire contains a 6-item screen-
ing part and a 12-item assessment part. All subjects
completed the MNA screening part. When subjects
scored ≤11 out of 14 points on the screening part
(indicative of increased risk for protein/energy malnu-
trition), the 12-item assessment part was completed as
well and a total score was calculated (MNA total = sum
of scores on screening part and assessment part; max-
imum score = 30, a score between 17 and 23.5 is
indicative of risk for protein/energy malnutrition, a
score lower than 17 is indicative for malnutrition). BMI
and calf circumference are part of the MNA screening
and total score, respectively.
Subject characteristics and nutritional supplement
use
Subject characteristics that were collected for the
study included age, gender, education (years of for-
mal education after finishing primary school), and
the MMSE score (a short cognitive test with a score
ranging from 0 [severe cognitive deficit] to 30 [no cog-
nitive deficit]). Furthermore, the health status of the
healthy controls was assessed using the Cumulative
Illness Rating Scale for Geriatrics (CIRS-G), which
measures chronic medical conditions while consider-
ing the severity of chronic diseases in elderly [22].
Diseases are scored by organ systems and grouped
into 14 categories. Each category is scored on severity,
ranging from 0 (no problem) to 4 (extremely severe).
For this study, the CIRS-G total score was calculated
(i.e., the sum of scores on the 14 categories, maximum
score = 56). If applicable, information was collected on
the use of nutritional supplements.
Ethics
Written informed consent was obtained from
patients and their caregivers and the healthy controls
prior to study participation. The Ethics Committee of
each participating study center reviewed and approved
the protocol. The study was conducted in accordance
with the Declaration of Helsinki, the International
Conference on Harmonization Guidelines for Good
Clinical Practice as appropriate for nutritional products
and the local laws and regulations of the Netherlands.
Biochemical analyses
Blood was collected in tubes containing ethylenedi-
aminetetraacetic acid. All samples were centrifuged
(1300 g, 15 min, 4◦C), and plasma and erythrocyte
aliquots were stored at −80◦C until analysis at a
central laboratory. Plasma folate and vitamin B12
levels were determined using a competitive protein
binding ligand assay, plasma B6 levels were mea-
sured by high-performance liquid chromatography
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(HPLC). HPLC-electrochemical detection of plasma-
free choline was performed according to a method
adapted from Fossati et al. [23] as described pre-
viously [24]. Plasma albumin was determined using
a colorimetric kit, and plasma selenium levels were
measured using graphite furnace atomic absorp-
tion spectrometry. A chemiluminescent microparticle
immuno assay (ARCHITECT assay) was used to
determine plasma vitamin D (total 25-hydroxyvitamin
D) levels. Plasma vitamin A (retinol) and vitamin
E (-tocopherol) levels were determined simulta-
neously by HPLC, using ultraviolet-absorbance for
detection of retinol and fluorometric properties for
detection of -tocopherol, by comparing with stan-
dard solutions [25]. For the determination of plasma
Hcy levels, thiol amino acids (free and protein-
bound) were reduced with tri-n-butylphosphine. After
precipitation with trichloroacetic acid, thiol groups
were derivatized with ammonium 7-fluorobenzo-2-
oxa-1,3-diazole-4-sulfonate, followed by separation
using HPLC with a fluorescence detector [26, 27]. In
order to determine plasma uridine levels, perchloric
acid was added to the sample. Uridine was extracted
by vortexing the solution, followed by separation from
other nucleotides/nucleosides using reversed-phase
HPLC [28]. Uridine was quantified by measuring its
absorbance compared with a standard. Fatty acid com-
positions of the erythrocyte lipid fraction and the
plasma phospholipid fraction were analyzed qualita-
tively on a gas chromatograph after extraction of the
lipids from the erythrocytes/plasma (plasma phospho-
lipids were separated from the other lipid classes in
plasma by solid phase extraction) and a methylation
step [29–32].
The analysis of plasma Hcy levels was repeated due
to relatively high interassay variations in the analyses.
Results from the second analysis were used for statis-
tical comparisons due to lower interassay variations in
the second compared with the first analysis. Also, the
analysis of plasma uridine levels was performed twice,
because the assay is sensitive to variation. Pooled data
from these analyses were used for statistical compar-
isons as there were no clear indications to use either
one of the analyses.
Statistical analyses
Statistical analyses were performed using SAS®
software (SAS Enterprise Guide 4.3 for Windows, SAS
Institute Inc., Cary, NC, USA). Data are presented as
means ± standard deviation (SD) unless stated other-
wise. Statistical significance was set at p < 0.05.
Given the exploratory nature of the study, no sample
size calculations were performed. Despite the attempt
to select a group of healthy controls with a mean age
comparable to the AD patients, there was an age differ-
ence at baseline between the healthy controls (n = 98)
and AD patients (n = 84) (respectively 70.4 ± 10.1 ver-
sus 74.2 ± 7.6 years, p = 0.005). To overcome this
imbalance at baseline, it was decided to exclude the
five oldest AD patients and the five youngest healthy
controls from the dataset prior to the main statisti-
cal analyses. Indeed, this resulted in a better balance
between groups with respect to age (Table 1), while
other subject characteristics at baseline did not change.
Therefore, data from 93 healthy controls and 79 AD
patients were used for the analyses presented here.
Differences between AD patients and healthy con-
trols were primarily analyzed using an independent
samples t-test. The non-parametric Mann-Whitney
test was used for parameters with a non-normal
distribution. As a sensitivity analysis, additional
between-group analyses were performed using anal-
ysis of covariance (ANCOVA) to correct for the
potential confounders ‘age’ (continuous; years), ‘nutri-
tional supplement use’ (dummy variable; yes/no),
‘use of lipid-modifying agents’ (dummy variable;
yes/no), and ‘years of education’ (continuous; years).
As some subjects used nutritional supplements, a spe-
cific dummy variable for nutritional supplement use
was defined for each outcome parameter. Results of
the ANCOVA analyses were compared with those of
the t-test. No correction for multiple testing was per-
formed, and, in line with the exploratory character of
the study, differences in levels between groups were
tested for each parameter separately using an alpha
level of 0.05.
Two AD patients and one healthy control were
excluded from the analysis of vitamin B6, vitamin
B12, folate, choline, and Hcy because of the recent
use of vitamin B12 injections, which might interfere
with plasma levels of these parameters.
RESULTS
Subject characteristics of both the AD patients and
the healthy controls are shown in Table 1. There
were no significant differences between groups for
age (t-test, p = 0.125) and gender (Fisher’s Exact test,
p = 0.760). Years of education was significantly higher
in healthy controls compared with AD patients (median
[range], 5.0 [0.0–25.0] versus 4.0 [0.0–16.0], Mann-
Whitney test, p = 0.005). The total MMSE score was
significantly higher in healthy controls compared with
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Table 1
Subject characteristics
Healthy controls (n = 93) Mild AD (n = 79) p-value
Age, years [range] 71.5 (9.3) [53 90] 73.4 (7.2) [54–84] 0.125∗
Male, n (%) 43 (46.2%) 39 (49.4%) 0.760†
Years of education beyond primary school 5.0 [0.0–25.0] 4.0 [0.0–16.0] 0.005‡
MMSE, total score 29.0 [23.0–30.0] 25.0 [20.0–30.0] <0.001‡
CIRS-G, total score 3.76 – n/a
Nutritional supplement use, n (%) 13 (14.0%) 12 (15.2%) 0.832†
Multivitamins 4 (4.3%) 1 (1.3%) 0.376†
Vitamin E 0 1 (1.3%) 0.459†
Vitamin D and analogues 4 (4.3%) 2 (2.5%) 0.688†
Vitamin B complex, plain 0 1 (1.3%) 0.459†
Hydroxocobalamin 1 (1.1%) 2 (2.5%) 0.594†
Folic acid 0 1 (1.3%) 0.459†
Calcium 4 (4.3%) 5 (6.3%) 0.734†
Other 4 (4.3%) 0 0.126†
Lipid-modifying agents use, n (%) 20 (21.5%) 31 (39.2%) 0.013†
AD, Alzheimer’s disease; CIRS-G, Cumulative Illness Rating Scale for Geriatrics; MMSE, Mini-Mental State Examination; –, not measured,
n/a, not applicable. Data are mean (standard deviation) or median [range]. ∗T-test; †Fisher’s exact test; ‡Mann-Whitney test.
AD patients (median [range], 29.0 [23.0–30.0] versus
25.0 [20.0–30.0], Mann-Whitney test, p < 0.001), sug-
gestive of a cognitively intact, healthy control group
versus a very early AD patient group. Moreover, the
CIRS-G score in the healthy controls (3.76) was indica-
tive of low co-morbidity. The number of subjects using
one or more nutritional supplements was comparable
between healthy controls and AD patients (13 (14.0%)
versus 12 (15.2%), Fisher’s Exact test, p = 0.832),
while the number of subjects using one or more lipid-
modifying agents was higher in the group of AD
patients compared with healthy controls (31 (39.2%)
versus 20 (21.5%), Fisher’s Exact test, p = 0.013).
Plasma micronutrients
Results for the comparison of plasma micronutri-
ent levels between the AD patients and the healthy
controls are shown in Table 2. Plasma selenium and
uridine levels were significantly lower in AD patients
compared with healthy controls (t-test, respectively
p < 0.001 and p = 0.046). There was a trend for lower
plasma vitamin D levels in AD patients compared with
healthy controls (t-test, p = 0.084). No significant dif-
ferences were observed between the healthy controls
and AD patients for plasma levels of folate, choline,
vitamin B6, vitamin B12, Hcy, vitamin A, vitamin E,
and albumin.
Correction for the potential confounders did not
affect any of the observed differences, except for the
difference in plasma vitamin D levels, which was
not significant after correction for the confounders
(ANCOVA, F(1, 166) = 2.34, p = 0.128).
Table 2
Descriptive statistics for plasma micronutrients, anthropometrics,
and malnutrition scoring for mild stage AD patients and healthy
controls
Healthy controls Mild AD p-value∗
(n = 93) (n = 79)
Plasma micronutrients
Homocysteine (M) 13.59 (5.27) 13.84 (5.65) 0.771
Folate (nM) 17.53 (8.59) 16.07 (10.12) 0.309
Choline (M) 8.45 (2.31) 8.79 (2.19) 0.345
Vitamin B12 (pM) 314.5 (98.4) 348.4 (188.8) 0.158
Vitamin B6 (nM) 61.28 (44.73) 57.85 (47.27) 0.631
Uridine (M) 3.38 (1.29) 3.03 (0.95) 0.046
Selenium (M) 1.18 (0.26) 1.04 (0.24) <0.001
Vitamin A (M) 3.30 (0.69) 3.46 (0.73) 0.151
Vitamin D (nM) 52.92 (22.23) 47.30 (19.69) 0.084
Vitamin E (M) 32.89 (7.23) 31.89 (9.07) 0.432
Anthropometrics
Body weight (kg) 73.79 (11.96) 74.89 (12.79) 0.560
Body height (m) 1.70 (0.08) 1.69 (0.08) 0.361
BMI (kg/m2) 25.4 (3.6) 26.2 (4.1) 0.212
Calf circumference (cm) 35.5 (3.1) 35.9 (3.2) 0.390
Malnutrition scoring
MNA screening score 13.2 (1.2) 12.6 (1.5) 0.008
MNA total score† 24.8 (1.6) 23.4 (2.7) 0.171
Albumin (g/L) 40.51 (2.83) 41.14 (2.76) 0.141
AD, Alzheimer’s disease; BMI, body mass index; MNA, Mini
Nutritional Assessment. Data are mean (standard deviation).
∗Independent samples t-test, except for MNA total score (see †)
†MNA total score: Healthy controls (n = 10), AD (n = 10). Fisher’s
Exact test.
Fatty acids in erythrocyte membrane and plasma
phospholipids
Table 3 shows the results of the between-group
comparisons of the erythrocyte and plasma fatty acid
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Table 3
Descriptive statistics for fatty acids in erythrocyte membranes and plasma phospholipids
Erythrocyte fatty acids Plasma phospholipid fatty acids
Healthy controls Mild AD p-value∗ Healthy controls Mild AD p-value∗
(n = 93) (n = 79) (n = 93) (n = 79)
EPA (%) 0.98 (0.40) 0.97 (0.44) 0.849 1.21 (0.62) 1.15 (0.72) 0.523
DHA (%) 3.44 (0.99) 2.99 (1.14) 0.006 3.63 (0.93) 3.55 (0.96) 0.572
DPA (%) 1.78 (0.36) 1.64 (0.54) 0.046 0.94 (0.17) 0.96 (0.17) 0.509
DHA+EPA (%) 4.42 (1.30) 3.95 (1.48) 0.028 4.84 (1.38) 4.69 (1.54) 0.511
n-3 LC-PUFA (%) 6.20 (1.54) 5.59 (1.92) 0.024 5.78 (1.44) 5.65 (1.60) 0.577
Palmitic acid (%) 24.82 (1.40) 26.64 (2.76) <0.001 27.90 (1.49) 28.52 (1.28) 0.005
Stearic acid (%) 9.00 (0.72) 9.12 (0.84) 0.309 13.19 (1.24) 12.87 (1.09) 0.077
Elaidic acid (%) 0.18 (0.11) 0.23 (0.11) 0.006 0.13 (0.05) 0.12 (0.06) 0.119
Oleic acid (%) 15.80 (1.72) 15.59 (1.54) 0.387 9.12 (1.20) 9.18 (1.47) 0.788
Cis-vaccenic acid (%) 1.14 (0.16) 1.14 (0.17) 0.981 1.34 (0.20) 1.36 (0.22) 0.515
Linoleic acid (%) 15.01 (2.53) 13.06 (2.41) <0.001 21.10 (2.86) 20.61 (2.71) 0.255
Gamma linolenic acid (%) 0.15 (0.10) 0.09 (0.09) <0.001 0.12 (0.06) 0.13 (0.07) 0.227
Alpha linolenic acid (%) 0.28 (0.10) 0.16 (0.09) <0.001 0.22 (0.09) 0.18 (0.06) <0.001
Stearidonic acid (%) 0.09 (0.04) 0.11 (0.13) 0.231 0.05 (0.01) 0.05 (0.01) 0.632
Dihomo gamma linolenic acid (%) 1.49 (0.30) 1.30 (0.33) <0.001 2.97 (0.77) 2.91 (0.68) 0.586
Arachidonic acid (%) 10.94 (1.43) 9.76 (2.69) <0.001 9.47 (1.84) 9.91 (2.38) 0.194
Cis docosapentaenoic acid (%) 0.63 (0.14) 0.70 (0.25) 0.026 0.21 (0.06) 0.21 (0.08) 0.790
AD, Alzheimer’s disease; DHA, docosahexaenoic acid; DPA, docosapentaenoic acid; EPA, eicosapentaenoic acid; n-3 LC-PUFA, n-3 long-chain
polyunsaturated fatty acids. Data are mean (standard deviation). ∗Independent samples t-test.
profiles. The percentage of DHA, docosapentaenoic
(DPA), DHA + eicosapentaenoic acid (EPA), linoleic
acid, alpha, gamma and dihomo gamma linolenic acid,
arachidonic acid, and n-3 LC-PUFA of total fatty acids
in the erythrocyte membrane was significantly lower
in the AD patients versus healthy controls, whereas
the percentage of palmitic acid, elaidic acid, and cis-
docosapentaenoic acid was higher in AD patients.
The proportion of the other analyzed fatty acids in
the erythrocyte membrane, including EPA, was not
significantly different between groups. In plasma phos-
pholipids, the percentage of alpha linolenic acid of total
fatty acids was significantly lower and the percentage
of palmitic acid significantly higher in AD patients ver-
sus healthy controls. The other fatty acids in plasma
phospholipids were not significantly different between
groups.
Correction for the potential confounders did not
affect the results of the fatty acid analyses, except for
the percentage of elaidic acid in plasma phospholipids,
which was significantly lower in AD patients versus
healthy controls after correction for the confounders
(ANCOVA, F(1, 159) = 3.96, p = 0.048).
Anthropometry
Calf circumference, body weight, height, and BMI
were not significantly different between AD patients
and healthy controls (Table 2). Also after correction for
potential confounders, no differences between groups
were observed.
Mini nutritional assessment
Results from the MNA questionnaire are shown
in Table 2. The MNA screening score was signifi-
cantly lower in the AD patients compared with the
healthy controls (12.6 ± 1.5 versus 13.2 ± 1.2, t-test,
p = 0.008). The MNA total score (applied to the subset
of subjects with an initial low MNA screening score
of ≤11, n = 10 in each group) was not significantly
different between groups (t-test, p = 0.171). The mean
MNA total score, however, was below the cut-off point
for normal nutritional status (i.e., <24.0) in the AD
patients (23.4 ± 2.7/n = 5 scored <24.0), but not in the
healthy controls (24.8 ± 1.6/n = 1 scored <24.0), sug-
gesting increased risk for protein/energy malnutrition
in only a small subgroup of AD patients.
Correction for potential confounders did not affect
any of the observed differences.
DISCUSSION
We found that plasma levels of selenium and uri-
dine were lower and plasma levels of vitamin D tended
to be lower in very mild AD patients (MMSE = 25.3)
compared with healthy controls. The fatty acid pro-
file in erythrocyte membranes also showed differences
between groups, including a lower proportion of
docosahexaenoic and linoleic acid and total n-3 LC-
PUFA and a higher proportion of palmitic and elaidic
acid in AD patients. The studied AD population was
not at nutritional risk: their MNA screening score was
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≥12 (<12 indicates risk on protein/energy malnutri-
tion) [10], their BMI was >23 kg/m2 [33], their calf
circumference >31 cm [10], and their albumin >35 g/L.
Therefore, the observed differences in nutrient levels
seem unlikely to have originated from protein/energy
malnutrition. However, based on this study we cannot
exclude that the nutritional differences measured are
caused by differences in intake secondary to the cogni-
tive decline. Other studies have proven compensatory
neuronal activity in AD, which make an intrinsic short-
age of certain micronutrients linked to increased needs
more likely [34]. Moreover, specific nutrient intake
deficiencies and weight loss may occur in AD despite
adequate or even increased caloric intake, possibly due
to defects in systemic nutrient homeostasis such as
malabsorption and decreased interest in specific nutri-
tional components [35]. Although unintended weight
loss frequently occurs in AD (approximately 40% of
patients) and has been reported during all stages of the
disease [36, 37], the mild AD patients in this study did
not suffer from energy malnutrition and had a relatively
high mean BMI. This suggests that caloric intake was
adequate in the currently studied mild AD population,
but this was not specifically measured. It has recently
been shown that BMI might even increase in preva-
lent AD and that changes in BMI during disease may
depend on the patient’s initial BMI [38]. Our results
from the MNA questionnaire are in agreement with a
recent study of the MNA in Dutch AD patients that
showed that outpatients of a memory clinic showed no
protein-energy malnutrition, while a subgroup (14%)
showed higher risk on such malnutrition [39]. In addi-
tion, the findings on nourishment status in the currently
studied AD patients are in line with literature data,
which suggest a positive association between preva-
lence of (risk of) protein/energy malnutrition and stage
of AD [11–14, 39].
Many studies have compared levels of nutrients
between AD patients and controls. In a recent meta-
analysis of such trials, a similar trend as in this study
was found for lower vitamin D levels in AD patients
[9]. Furthermore, lower levels of vitamin A, B12, E,
and folate in AD patients compared with cognitive
intact elderly controls were observed. In the present
study, no differences between groups in the levels of
these vitamins were observed, which may be explained
by several factors. Firstly, in the current study very
mild AD patients were included, whereas studies in the
meta-analysis included patients with a more advanced
stage of the disease: differences in certain nutrients
might only become apparent in more advanced stages
of the disease. Secondly, differences in dietary intake or
habits between studies performed in different countries
may contribute to these findings and the current study
was performed in one country only. Finally, the sam-
ple size may have been too small to detect differences
between groups in certain nutrients.
Lower selenium levels as currently found are also
described in other [40, 41], but not in all studies [42,
43]. Selenium is a micronutrient which is involved
in several molecular pathways that are thought to be
important in the progression of AD [44]. It is, for
instance, part of the antioxidant enzyme glutathion-
peroxidase which helps to protect lipid precursors and
the resulting membrane components from lipid perox-
idation. Lower plasma selenium levels in AD patients
compared with healthy controls may have an associa-
tion with the process of oxidative stress known to be
present in AD. To compensate for a possible increased
use of selenium in AD, a higher intake might be
necessary.
Several differences in fatty acid levels in erythro-
cyte membranes were observed between groups in
the present study, including lower proportions of n-
6 and n-3 polyunsaturated fatty acids in mild AD
patients. These differences are in line with reported
lower dietary intake of linoleic and alpha linolenic acid
and DHA in early AD compared with age-matched
controls [45]. The observed lower circulating levels
of n-6 fatty acids are generally believed not to be of
concern due to their high availability in foods through
plant oils and subsequent high and probably abundant
tissue levels [46]. In addition, we found higher levels
of the trans fatty acid elaidic acid in erythrocyte mem-
branes of the AD patients. Trans fatty acids have been
suggested to enhance amyloidogenic processing of the
amyloid precursor protein and increase the production
and aggregation of A in vitro [47]. However, the sug-
gested link between trans fatty acid intake and AD
risk or cognitive decline is not consistently supported
by cohort studies showing either a positive association
[48] or no association [49, 50].
In the current study, no significant differences in
plasma DHA, EPA, and n-3 LC-PUFA levels were
found between groups. Levels of n-3 LC-PUFA in
plasma, however, are a poorer marker of long term
dietary intake than levels in erythrocyte membranes
[51]. The observed lower erythrocyte DHA and total n-
3 LC-PUFA in the mild AD patients are consistent with
previous observations [52]. Recently, reduced activity
of the last step enzyme in DHA synthesis pathway, per-
oxisomal D-bifunctional protein was found in the liver
of AD patients and this coincided with lower DHA
levels in the brain and liver tissue [53]. This metabolic
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change may contribute to the lower DHA and not EPA
erythrocyte membrane levels as currently found and is
consistent with a recent meta-analytic review reporting
lower plasma levels of DHA and total n-3 LC-PUFA
in dementia patients [54].
The plasma levels of uridine were lower in AD
patients in the present study. This finding confirms the
results of a very recent study reporting lower plasma
uridine levels in AD patients versus healthy controls
[55]. Although the cause of these lower levels of uri-
dine is unclear, it has been speculated that de novo
synthesis of uridine in the liver may be reduced in AD
[8]. The lower uridine observed in the plasma of AD
patients is likely to result in less transport of uridine
into the brain as uridine readily enters the brain via the
blood-brain barrier high affinity transporter of nucleo-
sides CNT2 [56]. Uridine is, via the Kennedy pathway,
a precursor in the synthesis of phospholipids in neu-
ronal membranes, which are depleted in AD [57, 58].
Combined dietary enrichment of uridine and DHA has
been reported to promote the synthesis of brain phos-
pholipids, hippocampal dendritic spines, and synaptic
proteins, all prerequisites for synaptogenesis [59]. In
AD, cerebrospinal fluid uridine levels [60] and hip-
pocampal levels of DHA [61, 62] were found to be
lower than in controls, which together may reflect a
reduced capacity for neuronal membrane synthesis and
may result in inability to compensate for the synaptic
loss associated with AD and be associated with lower
levels in the circulation. Although tissue target levels
of uridine and DHA are not well defined for the general
population, they should probably be higher for people
with AD provided their role in compensational neu-
ronal membrane synthesis. Further research is needed
to elucidate the cause and possible clinical implications
of lower circulating uridine and DHA levels in AD.
Decreased levels of certain nutrients as observed in
AD patients suggest a potential role for the supplemen-
tation of specific nutrients in the management of AD.
Until now, several intervention studies investigated the
effects of supplementation with single nutrients, for
instance vitamin B12, vitamin E, or n-3 LC-PUFA in
dementia patients, showing no or little improvements
of cognitive function and other outcomes [63–65]. The
outcomes of single nutrient studies may be explained
by the fact that nutrients most likely act in a synergistic
way [66]. The findings of the current study are in line
with this, since several nutrients, rather than a single
nutrient, were observed to be present in lower levels.
An intervention with a specific combination of nutri-
ents in the form of a medical food has been shown to
improve memory performance of drug-naı¨ve patients
with mild AD and has been suggested to preserve func-
tional connectivity in AD [17, 67]. Together, these
data may suggest that combinations of nutrients can
be more powerful than single nutrients, as there may
be a positive interaction between them. A similar syn-
ergistic effect of a complex combination of nutrients
has recently been described for the Mediterranean diet
enriched with walnut oil for cardiovascular endpoints
[68].
The present study has some limitations: 1) Con-
trol subjects are not precisely matched for age and
gender. The average age of AD patients is almost 2
years higher and there are slightly more men in the
AD group (49.4% versus 46.2%). These differences
may have influenced the results. However, analyses on
data of 66 pairs of age- and gender-matched subjects
and excluding subjects using nutritional supplements
yielded similar results (data not shown). 2) No data
were collected on dietary intake of the study sub-
jects, so the possible contribution of (differences in)
dietary intake (specific (micro)nutrients and/or caloric
intake) on the results cannot be determined. 3) Due
to the exploratory character of the study, no correc-
tion for multiple testing was performed. To confirm
current study findings, further research is warranted.
4) To avoid the influence of regional differences in
nutrient levels via for instance different dietary habits
or food fortification, this substudy was performed in
one small country with relatively homogenous food
habits, the Netherlands. This may, however, limit its
representation for other regions.
In conclusion, the study results showed lower levels
of some micronutrients, a different fatty acid profile
in erythrocyte membranes, and a slightly, but signif-
icantly lower MNA screening score in very mild AD
patients compared with healthy controls, whereas the
AD patients were neither malnourished nor at risk of
malnutrition. These data suggest that in a very early
stage of AD and in the absence of protein/energy
malnutrition, subtle differences in nutrient status are
present as compared to healthy controls. Given the pro-
posed role of nutrients and nourishment status in AD
pathology and progress, these data need to be corrobo-
rated in an independent sample, possibly also including
preclinical and prodromal stages of AD to study when
these changes occur in the disease progress.
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